Cargando…

Phase II trial of trimelamol in refractory ovarian cancer.

Trimelamol is an analogue of hexamethymelamine which exhibited activity against refractory ovarian cancer in phase I clinical trial. The dose limiting toxicity was leukopenia. In a phase II study, 42 patients with recurrent, or platinum-complex resistant, advanced ovarian cancer were treated using t...

Descripción completa

Detalles Bibliográficos
Autores principales:	Judson, I. R., Calvert, A. H., Gore, M. E., Balmanno, K., Gumbrell, L. A., Perren, T., Wiltshaw, E.
Formato:	Texto
Lenguaje:	English
Publicado:	Nature Publishing Group 1991
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1971798/ https://www.ncbi.nlm.nih.gov/pubmed/1997112

Ejemplares similares

Cisplatin/carboplatin cross-resistance in ovarian cancer.
por: Gore, M. E., et al.
Publicado: (1989)

Paclitaxel (Taxol) in relapsed and refractory ovarian cancer: the UK and Eire experience.
por: Gore, M. E., et al.
Publicado: (1995)

Low central nervous system penetration of N2,N4,N6,-trihydroxymethyl-N2,N4,N6,-trimethylmelamine (Trimelamol): a cytotoxic s-triazine with reduced neurotoxicity.
por: Judson, I. R., et al.
Publicado: (1986)

A randomised study of carboplatin vs sequential ifosfamide/carboplatin for patients with FIGO stage III epithelial ovarian carcinoma. The London Gynaecologic Oncology Group.
por: Perren, T. J., et al.
Publicado: (1993)

Phase I trial with pharmacokinetics of CB10-277 given by 24 hours continuous infusion.
por: Foster, B. J., et al.
Publicado: (1993)

A phase II feasibility study of carboplatin followed by sequential weekly paclitaxel and gemcitabine as first-line treatment for ovarian cancer
por: Harries, M, et al.
Publicado: (2004)

A Cancer Research Campaign (CRC) phase II trial of CB10-277 given by 24 hour infusion for malignant melanoma.
por: Bleehen, N. M., et al.
Publicado: (1994)

Phase II randomized study of PM01183 versus topotecan in patients with platinum-resistant/refractory advanced ovarian cancer
por: Poveda, A., et al.
Publicado: (2017)

Phase II trial of tamoxifen and goserelin in recurrent epithelial ovarian cancer
por: Hasan, J, et al.
Publicado: (2005)

Phase II trial of ponatinib in patients with bevacizumab‐refractory glioblastoma
por: Lee, Eudocia Q., et al.
Publicado: (2019)

Randomised phase II trial of weekly ixabepilone ± biweekly bevacizumab for platinum-resistant or refractory ovarian/fallopian tube/primary peritoneal cancer
por: Roque, Dana M., et al.
Publicado: (2022)

The clinical correlates of serum CA125 in 169 patients with epithelial ovarian carcinoma.
por: Hawkins, R. E., et al.
Publicado: (1989)

Targeted anti-vascular therapies for ovarian cancer: current evidence
por: Hall, M, et al.
Publicado: (2013)

A negative phase II trial methylene dimethane sulphonate in advanced ovarian cancer (Cancer Research Campaign Phase I/II Trials Committee).
por: Smith, D. B., et al.
Publicado: (1988)

Phase II biomarker trial of a multimarker diagnostic for ovarian cancer
por: Edgell, Tracey, et al.
Publicado: (2010)

Phase II evaluation of mitozolomide in ovarian cancer.
por: Harding, M., et al.
Publicado: (1988)

Randomised phase II trial of irinotecan plus S-1 in patients with gemcitabine-refractory pancreatic cancer
por: Ioka, T, et al.
Publicado: (2017)

Continuous low dose Thalidomide: a phase II study in advanced melanoma, renal cell, ovarian and breast cancer
por: Eisen, T, et al.
Publicado: (2000)

Tailored-dose chemotherapy with gemcitabine and irinotecan in patients with platinum-refractory/resistant ovarian or primary peritoneal cancer: a phase II trial
por: Tate, Shinichi, et al.
Publicado: (2020)

Ovarian Cancer
por: Judson, I.
Publicado: (1993)

Multicenter phase II trial of modified FOLFIRINOX in gemcitabine-refractory pancreatic cancer
por: Chung, Moon Jae, et al.
Publicado: (2018)

A phase II trial of capecitabine (Xeloda®) in recurrent ovarian cancer
por: Vasey, P A, et al.
Publicado: (2003)

Combination chemotherapy with carboplatin, capecitabine and epirubicin (ECarboX) as second- or third-line treatment in patients with relapsed ovarian cancer: a phase I/II trial
por: Rothermundt, C, et al.
Publicado: (2006)

Randomized phase II study of the PDGFRα antibody olaratumab plus liposomal doxorubicin versus liposomal doxorubicin alone in patients with platinum-refractory or platinum-resistant advanced ovarian cancer
por: McGuire, William P., et al.
Publicado: (2018)

Preclinical, phase I and pharmacokinetic studies with the dimethyl phenyltriazene CB10-277.
por: Foster, B. J., et al.
Publicado: (1993)

Phase II trials of fosquidone, (GR63178A), in colorectal, renal and non-small cell lung cancer. CRC Phase II Clinical Trials Committee.
por: Kaye, S. B., et al.
Publicado: (1992)

A multi-institutional phase II trial of bevacizumab for recurrent and refractory meningioma
por: Kumthekar, Priya, et al.
Publicado: (2022)

Response of patients in phase II studies of chemotherapy in ovarian cancer: implications for patient treatment and the design of phase II trials.
por: Blackledge, G., et al.
Publicado: (1989)

A phase II trial of goserelin (Zoladex) in relapsed epithelial ovarian cancer.
por: Lind, M. J., et al.
Publicado: (1992)

A phase Ib trial of docetaxel, carboplatin and erlotinib in ovarian, fallopian tube and primary peritoneal cancers
por: Vasey, P A, et al.
Publicado: (2008)

S‐1 plus Raltitrexed for Refractory Metastatic Colorectal Cancer: A Phase II Trial
por: Chen, Ye, et al.
Publicado: (2019)

Nivolumab and ipilimumab in recurrent or refractory cancer of unknown primary: a phase II trial
por: Pouyiourou, Maria, et al.
Publicado: (2023)

Phase II trials of rhizoxin in advanced ovarian, colorectal and renal cancer.
por: Kerr, D. J., et al.
Publicado: (1995)

Randomised phase II trial of S-1 plus oxaliplatin vs S-1 in patients with gemcitabine-refractory pancreatic cancer
por: Ohkawa, S, et al.
Publicado: (2015)

Phase I/II clinical trial of temsirolimus and lenalidomide in patients with relapsed and refractory lymphomas
por: Major, Ajay, et al.
Publicado: (2021)

The impact of computed tomography and ultrasonography on the management of patients with carcinoma of the ovary.
por: Gore, M. E., et al.
Publicado: (1989)

Phase II trial of ribociclib and letrozole in patients with relapsed oestrogen receptor-positive ovarian or endometrial cancers
por: Colon-Otero, Gerardo, et al.
Publicado: (2020)

Phase II study of pembrolizumab in refractory esophageal cancer with correlates of response and survival
por: de Klerk, Leonie K, et al.
Publicado: (2021)

Phase II trial of irinotecan plus docetaxel in cisplatin-pretreated relapsed or refractory oesophageal cancer
por: Lordick, F, et al.
Publicado: (2003)

Protracted oral etoposide in epithelial ovarian cancer: a phase II study in patients with relapsed or platinum-resistant disease.
por: Seymour, M. T., et al.
Publicado: (1994)

Cannot write session to /tmp/vufind_sessions/sess_qorkd81i2lf14lvhedau048pcl